Vitamin D Supplementation to Obese Chinese Males

Not Applicable

Completed

• Conditions: Obesity; Insulin Resistance

• Registration Number: NCT01781169
• Lead Sponsor: Shenzhen Center for Chronic Disease Control

Brief Summary

Hypothesis: Oral Supplementation of Vitamin D can Reduce Hypersecretion of Parathyroid Hormone and Insulin Resistance in Obese Chinese Males.

Protocol: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) or eight weeks to the obese males compared with the normal-weight males. Index measures were conducted at baseline and endpoint.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-04
• Primary Completion: 2011-12
• Study Completion: 2012-12
• Study First Submitted: 2013-01-25
• Study First Submitted QC: 2013-01-29
• Study First Posted: 2013-01-31
• Results First Submitted: 2013-05-29
• Results First Submitted QC: 2013-07-26
• Status Verified: 2013-09
• Last Update Submitted: 2013-09-27
• Results First Posted: 2013-09-30
• Last Update Posted: 2013-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 43

Inclusion Criteria

• body mass index (BMI) ≥ 28kg/m2 or 18.5 ≤ BMI < 24 (kg/m2)
• non vegetarian Han Chinese and did not smoke, drink, nor take vitamin D supplements for > 2 y
• fasting serum glucose < 7.0 mmol/L
• serum glucose of 2 hr after 75 g oral glucose loading < 11.1 mmol/L
• normal functioning of liver and kidney evaluated by alkaline phosphatase, aspartate aminotransferase, creatinine, and uric acid

Exclusion Criteria

• not match the above inclusion criteria
• diagnosed as having any organic diseases were excluded

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L)	Endpoint and baseline of the 8 weeks' trial

Trial Locations

Locations (1)

Shenzhen Center for Chronic Disease Control; 🇨🇳 Shenzhen, Guangdong, China